Medindia

X

Motesanib Does Not Make a Mark in NSCLC Study

by Savitha C Muppala on  April 1, 2011 at 8:07 PM Drug News   - G J E 4
Motesanib, a drug meant for those cancers which are difficult to treat , has unfortunately not lived up to expectations in the phase III trial.

 Infact, it did not make any significant contribution in improving the survival rate among victims of non-small cell lung cancer (NSCLC).
 Motesanib Does Not Make a Mark in NSCLC Study
Motesanib Does Not Make a Mark in NSCLC Study
Advertisement

Nearly 1,090 patients with advanced nonsquamous NSCLC were part of the study.

Advertisement


Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All